Cargando…
Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients
The coronavirus disease 2019 (COVID-19) pandemic has become a huge obstacle to the health system due to the high rate of contagion. It is postulated that intravenous immunoglobulins (IVIG) can lower the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related inflammation and prevent the...
Autores principales: | Kwapisz, Dorota, Bogusławska, Joanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Masson SAS.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160523/ https://www.ncbi.nlm.nih.gov/pubmed/37167723 http://dx.doi.org/10.1016/j.biopha.2023.114851 |
Ejemplares similares
-
Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19 – A theoretical perspective
por: Yaqinuddin, Ahmed, et al.
Publicado: (2021) -
Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations
por: Hooper, John A.
Publicado: (2008) -
Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series
por: Mohtadi, Negar, et al.
Publicado: (2020) -
Hydroxychloroquine-Induced Myopathy Responding to Intravenous Immunoglobulin (IVIG)
por: Almoallim, Hani, et al.
Publicado: (2023) -
Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)